OVERALL COMPLETE REMISSION1

65% CR/CRi (n=35/54)

DEEP1

52%

CR (n=28/54)

DURABLE1

13.6MONTHS

mDOR in responders
(CR/CRi)

RAPID5

1.5 month median time to
response
(range: 0.9-3.1 months)

ALL=acute lymphoblastic leukemia; CAR=chimeric antigen receptor; CR=complete remission; CRi=complete remission with incomplete hematologic recovery; DOR=duration of remission; FDA=Food and Drug Administration; mDOR=median duration of remission; OS=overall survival; RFS=relapse-free survival; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. KYMRIAH® (tisagenlecleucel). Prescribing information. Novartis Pharmaceuticals Corporation; 2021. 3. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502. 4. U.S. FDA approves Kite's Tecartus® as the first and only CAR T for adults with relapsed or refractory B-cell acute lymphoblastic leukemia. News release. Kite, a Gilead Company; October 1, 2021. Accessed October 1, 2021. https://www.businesswire.com/news/home/20211001005719/en/